Positive early efficacy signal in a difficult indication could drive near-term speculative interest given micro-cap status. However, the company has a history of dilutive offerings and negative cash flow — monitor for any concurrent capital raise announcement. Full PFS/OS data in coming months will determine whether this signal is durable.
Price Chart
Executive Summary
Can-Fite reported positive Phase 2a data for namodenoson in advanced pancreatic cancer, showing >30% stable disease, 35% of patients remaining on therapy, and one patient beyond 16 months. The study met its primary safety endpoint with a favorable profile. Full efficacy results (PFS, OS) are expected in coming months.
Key Facts
- Phase 2a study of namodenoson in advanced pancreatic cancer: >30% stable disease, 35% of patients remain on therapy, one patient beyond 16 months.
- Study met primary safety endpoint; no new safety signals identified.
- 20 evaluable patients enrolled; open-label trial in heavily pretreated population.
- Full efficacy analyses (PFS, OS) top-line results expected in coming months.
- Namodenoson has FDA Orphan Drug Designation for pancreatic cancer.
- Market cap ~$6M; company has history of dilutive offerings and negative cash flow per 20-F.
Financial Impact
No financial figures provided in filing; clinical-stage company with no revenue from namodenoson.
Risk Factors
- Early-stage data (Phase 2a, 20 patients) — efficacy signal may not replicate in larger trials.
- Company has history of dilutive offerings and going concern risk per 20-F; any equity raise could offset positive sentiment.
- Full efficacy results not yet reported; stock may be volatile on interim data.
- Micro-cap ($6M) with low liquidity — price moves may be exaggerated.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-049750 |
| Document: ea0288500-6k_canfite.htm | 0001213900-26-049750 |
| Document: 0001213900-26-049750-index-headers.html | 0001213900-26-049750 |
| Document: 0001213900-26-049750-index.html | 0001213900-26-049750 |
| Document: 0001213900-26-049750.txt | 0001213900-26-049750 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $1.72 | awaiting T+5 | awaiting T+5 | $1.65 (−4.07%) |
Oct 13, 2026 15d ago | EFFECT | $1.95 $1.89 | ▲ +3.08% | ▲ +1.93% | $1.65 (+15.38%) |
Oct 13, 2026 15d ago | EFFECT | $1.95 $1.89 | ▲ +3.08% | ▲ +1.93% | $1.65 (+15.38%) |
Sep 14, 2026 6w ago | EFFECT | $2.30 $2.22 | ▲ +3.48% | ▲ +3.58% | $1.65 (+28.26%) |
Sep 9, 2026 6w ago | 6-K | $2.19 $2.24 | ▲ +2.28% | ▲ +3.38% | $1.65 (−24.66%) |
Sep 3, 2026 7w ago | 6-K | $2.35 $2.33 | ▼ −0.85% | ▲ +0.30% | $1.65 (−29.79%) |
Sep 2, 2026 7w ago | 6-K | $2.36 $2.16 | ▼ −8.47% | ▼ −7.52% | $1.65 (−30.08%) |
Sep 2, 2026 7w ago | Press Release | $2.36 $2.16 | ▲ +8.47% | ▲ +7.52% | $1.65 (+30.08%) |
Sep 2, 2026 7w ago | 6-K | $2.36 $2.16 | ▼ −8.47% | ▼ −7.52% | $1.65 (−30.08%) |
Aug 17, 2026 10w ago | 6-K | $3.58 $3.35 | ▼ −6.42% | ▼ −5.23% | $1.65 (−53.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers